David S Geldmacher1, Noam Y Kirson2, Howard G Birnbaum3, Sara Eapen3, Evan Kantor3, Alice Kate Cummings3, Vijay N Joish4. 1. Department of Neurology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 2. Analysis Group, Inc., Boston, MA, USA. Electronic address: nkirson@analysisgroup.com. 3. Analysis Group, Inc., Boston, MA, USA. 4. Bayer HealthCare Pharmaceuticals, Wayne, NJ, USA.
Abstract
OBJECTIVE: The objective of this study was to examine the effect of treatment timing on risk of institutionalization of Medicaid patients with Alzheimer's disease (AD) and to estimate the economic implications of earlier diagnosis and treatment initiation. METHODS: New Jersey Medicaid claims data (1997-2009) were used retrospectively to study the effect of treatment on time to institutionalization. Observed Medicaid payments were used to calculate savings from delayed institutionalization, adjusting for cost offsets resulting from concurrent changes in use of other medical services. RESULTS: Initiation of existing therapies at earliest symptomatic onset is predicted to delay institutionalization by 91 days, reducing Medicaid costs by $19,108/institutionalized patient. Incorporating an 18.5% cost offset from increased use of other medical services as well as drug costs associated with earlier treatment results in net savings of $12,687/patient. Projected annual Medicaid savings exceed $1 billion. CONCLUSION: Earlier treatment leads to a small delay in institutionalization among AD patients, resulting in significant costs savings to Medicaid.
OBJECTIVE: The objective of this study was to examine the effect of treatment timing on risk of institutionalization of Medicaid patients with Alzheimer's disease (AD) and to estimate the economic implications of earlier diagnosis and treatment initiation. METHODS: New Jersey Medicaid claims data (1997-2009) were used retrospectively to study the effect of treatment on time to institutionalization. Observed Medicaid payments were used to calculate savings from delayed institutionalization, adjusting for cost offsets resulting from concurrent changes in use of other medical services. RESULTS: Initiation of existing therapies at earliest symptomatic onset is predicted to delay institutionalization by 91 days, reducing Medicaid costs by $19,108/institutionalized patient. Incorporating an 18.5% cost offset from increased use of other medical services as well as drug costs associated with earlier treatment results in net savings of $12,687/patient. Projected annual Medicaid savings exceed $1 billion. CONCLUSION: Earlier treatment leads to a small delay in institutionalization among ADpatients, resulting in significant costs savings to Medicaid.
Authors: Maria Pisu; Roy C Martin; Liang Shan; Giovanna Pilonieta; Richard E Kennedy; Gabriela Oates; Young-Il Kim; David S Geldmacher Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Lisa Kirk Wiese; Christine L Williams; Debra Hain; David Newman; Christina P Houston; Carolina Kaack; James E Galvin Journal: Geriatr Nurs Date: 2020-10-08 Impact factor: 2.361
Authors: Noam Y Kirson; Urvi Desai; Ljubica Ristovska; Alice Kate G Cummings; Howard G Birnbaum; Wenyu Ye; J Scott Andrews; Daniel Ball; Kristin Kahle-Wrobleski Journal: BMC Geriatr Date: 2016-07-11 Impact factor: 3.921
Authors: Enrico R Fantoni; Anastasia Chalkidou; John T O' Brien; Gill Farrar; Alexander Hammers Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Noam Y Kirson; J Scott Andrews; Urvi Desai; Sarah B King; Sophie Schonfeld; Howard G Birnbaum; Daniel E Ball; Kristin Kahle-Wrobleski Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472